Elicio Therapeutics’ cancer vaccine—designed to train the immune system to attack KRAS-mutated tumors—continues to show strong promise. In a Phase 2 trial, it induced immune responses in 99% of evaluable pancreatic cancer patients, with 88% responding to their own tumor-specific mutation.